Canndoc
Canndoc is an Israel-based, GMP-certified producer of pharma-grade medical cannabis oils and inflorescences, serving 40,000+ Israeli patients via pharmacy networks (Super-Pharm, Givol, S.L.E/Teva) and international wholesale partners including Tilray, Organigram, and Aphria. It is a wholly-owned subsidiary of Nasdaq-listed InterCure Ltd.
- Company typePrivate
- Founded2008
- HeadquartersHerzliya, Israel
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Canndoc does
Canndoc Ltd. develops and supplies GMP pharma-grade medical cannabis products from its headquarters in Herzliya, Israel, operating as a wholly-owned subsidiary of InterCure Ltd. (NASDAQ: INCR; TASE: INCR). Founded in 2008 by Avner Neri Barak and active for more than 15 years, the company sells a portfolio of cannabis oils (in balanced, THC-dominant, and CBD-dominant formulations up to T20/C4 and a pure CBD isolate T0/C24) and dried-flower inflorescences, all manufactured to pharmaceutical Good Manufacturing Practice standards and meeting European, Canadian, and Israeli regulatory requirements. Its underlying technology stack rests on a proprietary genetic bank of 30+ unique cannabinoid profiles, full-spectrum oil extraction methods that preserve the original strain profile, and a proprietary clinical database covering 40,000+ patients and 500,000+ doses, which underpins a 10-trial clinical program across adult epilepsy, fibromyalgia, neuropathic pain, chemotherapy side effects, Parkinson's, rheumatoid arthritis, PTSD, and lumbar radiculopathy.
The company serves three end markets in parallel. In Israel it distributes through long-term pharmacy partnerships with Super-Pharm (the country's leading pharmacy chain), the Givol pharmacy chain, and S.L.E (a Teva subsidiary) under a physician-prescription model that targets patients with neuropathic pain, cancer pain, inflammatory bowel disease, PTSD, Parkinson's, epilepsy, multiple sclerosis, chemotherapy side effects, and related conditions. Internationally, Canndoc runs export-import agreements with Tilray, Aphria, and Organigram and an expanding portfolio of brand licenses (Cookies for Europe, Binske globally, TYSON 2.0 across Israel/Australia/UK/Germany/EU, plus Charlotte's Web, Humboldt, KOOTS CANNA, TOTEM, PurpleFarm, Space Labs, CRAFT, and Diamonds/Fotmer), enabling cross-border trade and market entry behind established consumer brands. Revenue mechanics are predominantly physical-product sales (oils and inflorescences) distributed through pharmacy channels in Israel and through wholesale supply agreements to large Canadian producers and licensed brand partners abroad; pricing is prescription-driven and not publicly disclosed.
Canndoc firmographics
Firmographics- Name
- Canndoc
- Legal name
- Canndoc Ltd.
- Website
- https://canndoc.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Canndoc is an Israel-based, GMP-certified producer of pharma-grade medical cannabis oils and inflorescences, serving 40,000+ Israeli patients via pharmacy networks (Super-Pharm, Givol, S.L.E/Teva) and international wholesale partners including Tilray, Organigram, and Aphria. It is a wholly-owned subsidiary of Nasdaq-listed InterCure Ltd.
- Ownership category
- akta.pro rank
Canndoc industry classification
Industry- Product category
- Pharmaceutical Medical Cannabis
- NAICS
- Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services) (CRANAFAI)
- akta.pro secondary industry
- Cannabis Dispensary + Ancillary Retail (Accessories, CBD/Hemp, Merchandise) (CRANAFAH)
Keywords
Where Canndoc is headquartered
LocationHeadquarters
- HQ city
- Herzliya
- HQ country
- Israel
- HQ region
- Middle East
Offices1 record
Markets served
Canndoc business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Others
Revenue model
- Medical Cannabis Product Sales: Production and sale of GMP-grade medical cannabis products including oils and inflorescences (dried flowers) with various THC/CBD ratios prescribed for conditions such as neuropathic pain, cancer pain, inflammatory bowel disease, PTSD, Parkinson's, and epilepsy
- International Trade and Export: International trade of medical cannabis products including import-export agreements with companies like Tilray, Organigram, and Aphria for cross-border distribution
Go-to-market motion2 records
Distribution channels4 records
Marketing channels5 records
Canndoc product offering
Product offeringCore offering
Canndoc produces and distributes GMP pharma-grade medical cannabis products, including a portfolio of cannabis oils in various THC/CBD ratios (balanced, THC-dominant, CBD-dominant, and pure CBD isolate) and dried flower inflorescences. Products are manufactured to pharmaceutical-grade standards and prescribed for conditions including neuropathic pain, cancer pain, epilepsy, PTSD, Parkinson's, inflammatory bowel disease, multiple sclerosis, and chemotherapy side effects. The company also operates brand partnerships distributing international cannabis brands through its pharmacy and international partner network.
Product overview
Canndoc is a GMP (Good Manufacturing Practice) pharma-grade medical cannabis company offering a comprehensive portfolio of pharmaceutical-quality cannabis products. The core product lines include cannabis oils (in various THC/CBD ratios from balanced to THC-dominant and CBD-dominant formulations including pure CBD isolate) and dried flower inflorescences. The company also operates multiple licensed brand partnerships including KOOTS CANNA, TOTEM, Binske, Cookies, Humboldt, Space Labs, CRAFT, PurpleFarm, Stars, and Diamonds (Fotmer), along with proprietary sub-brands like Canndoc BLACK, Canndoc TRP, and Shapes. Products cover regulatory requirements for European, Canadian, and Israeli markets, with varieties ranging from T0/C24 (pure CBD) to T20/C4 (high THC), prescribed for conditions including neuropathic pain, epilepsy, inflammatory bowel disease, PTSD, Parkinson's, and cancer-related symptoms. The company serves patients through pharmacy networks including Super-Pharm/Giv'ol and operates international partnerships for supply and distribution.
Differentiator
Problem solved
Functional benefit
Brands
- Canndoc Diamonds: Premium cannabis product line featuring strains like Gorilla Glue and Mango in full spectrum oil format
- Canndoc TRP
- Canndoc BLACK
- Canndoc Cali
- Canndoc Indoor Premium Craft
- PURAKA
- NAVAJO
- COYA
Products and services
- GMP Medical Cannabis Oils
Quantifiable outcome
- Served 40,000+ patients with millions of doses
- +2 more outcomes
Companies that use Canndoc
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Canndoc technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Canndoc partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- TYSON 2.0coreInterCure Ltd. partnered with TYSON 2.0 for distribution in Israel, Australia, United Kingdom, Germany and other EU countries.
- BinskecoreInterCure announced exclusive international partnership agreement with award-winning cannabis brand Binske for global market distribution.
- CookiescoreInterCure announced agreement with Cookies to expand the iconic cannabis brand across Europe, leveraging Cookies' strong brand recognition.
- Fotmer Life SciencesminorUruguayan cannabis company Fotmer Life Sciences signed a supply agreement to provide cannabis products to Canndoc, expanding supply chain sources.
- Charlotte's WebminorCharlotte's Web expanded into Israel through strategic alliance with InterCure (owner of Canndoc), bringing CBD products to the Israeli market.
- OrganigramcoreOrganigram sent first shipment of indoor-grown dried flower to Canndoc as part of an international strategic agreement representing the largest such deal to date for international cannabis trade.
- Super-PharmcoreLong-term partnership agreement for distribution of GMP medical cannabis products through Super-Pharm's pharmacy network across Israel.
- AphriacoreAphria Inc., a leading Canadian cannabis company, signed a strategic supply agreement with Canndoc for international product supply.
- TilraycoreCanndoc signed a cannabis import-export deal with Tilray, a leading Canadian cannabis company. This partnership resulted in Israel's first imported medical cannabis shipment, enabling cross-border trade and access to international cannabis products for the Israeli market.
- S.L.E (Teva)coreS.L.E (a subsidiary of Teva Pharmaceuticals) signed a deal to distribute Canndoc's GMP-approved products to pharmaceutical customers in Israel.
Scale indicators7 records
Recent moves9 records
Expansion highlights6 records
Canndoc competitors and assessment
Company assessmentDirect peers
- Organigram Holdings: Canadian licensed producer that signed one of Canndoc's largest international supply agreements. Compares as a multi-country medical cannabis producer serving European and Israeli channels.
- Charlotte's Web Holdings: CBD-focused cannabis wellness company that entered Israel through a strategic alliance with InterCure (Canndoc's parent). Comparable in standardized botanical cannabis products serving medical patients.
- Bol Pharma: Israeli medical cannabis cultivator and producer operating in the same regulatory environment and pharmacy distribution model as Canndoc. Directly comparable as a domestic Israeli GMP-certified competitor.
- Panaxia Pharmaceutical Industries: Israeli pharma-grade medical cannabis producer with similar GMP manufacturing standards and pharmacy-channel distribution. Closest direct domestic competitor to Canndoc in the Israeli market.
- Cookies Enterprises: Iconic US cannabis lifestyle brand partnered with InterCure/Canndoc to expand across Europe. Comparable as a premium cannabis brand leveraging Canndoc's international distribution platform.
- Tilray Brands: Global medical and adult-use cannabis producer with which Canndoc has an active import-export partnership. Directly comparable as a GMP-certified international medical cannabis producer serving pharmacy channels.
Emerging players
- Binske: Award-winning premium cannabis brand holding an exclusive international distribution partnership with InterCure/Canndoc. Comparable as a craft/lifestyle cannabis brand commercialized through Canndoc's platform.
Broad incumbents
- Canopy Growth Corporation: One of the largest Canadian cannabis producers with global medical and consumer brands. Overlaps with Canndoc in pharmaceutical-grade medical cannabis production and international distribution.
- Aurora Cannabis: Large Canadian licensed producer with established EU and international medical cannabis distribution. Comparable to Canndoc as a multi-jurisdictional GMP-certified producer, though operating at much larger scale.
Regional players
- Fotmer Life Sciences: Uruguayan organic cannabis producer with a supply agreement into Canndoc. Comparable as a Latin American GMP-grade producer accessing the Israeli/European market through Canndoc.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Canndoc social profiles
Digital presenceCanndoc compliance and trust
Trust signalCompliance1 record
Canndoc financial estimates
Financial estimateRevenue estimate
Valuation estimate
Canndoc leadership team
Management profileNumber of profiles
Profiles14 records
Canndoc funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Canndoc M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Canndoc
What does Canndoc do?
Canndoc produces and distributes GMP pharma-grade medical cannabis products, including a portfolio of cannabis oils in various THC/CBD ratios (balanced, THC-dominant, CBD-dominant, and pure CBD isolate) and dried flower inflorescences. Products are manufactured to pharmaceutical-grade standards and prescribed for conditions including neuropathic pain, cancer pain, epilepsy, PTSD, Parkinson's, inflammatory bowel disease, multiple sclerosis, and chemotherapy side effects. The company also operates brand partnerships distributing international cannabis brands through its pharmacy and international partner network.
Is Canndoc a public or private company?
Canndoc is a private company. It is classified as corporate owned and is currently operating.
When was Canndoc founded?
Canndoc was founded in 2008. It employs 51 to 100 people.
Where is Canndoc based?
Canndoc is headquartered in Herzliya, Israel, in the Middle East region.
How does Canndoc make money?
Two revenue lines are on record. Medical Cannabis Product Sales are the primary driver. The others are international Trade and Export.
Who are Canndoc's main competitors?
Direct peers on record are Organigram Holdings, Charlotte's Web Holdings, Bol Pharma, Panaxia Pharmaceutical Industries, Cookies Enterprises and Tilray Brands. Binske is listed as an emerging player. Broad incumbents are Canopy Growth Corporation and Aurora Cannabis. Fotmer Life Sciences is listed as a regional player.
Does Canndoc have an API?
No public API is recorded for Canndoc.
What industry is Canndoc in?
Canndoc's product category is Pharmaceutical Medical Cannabis. Its primary akta.pro industry code is CRANAFAI, Cannabis Dispensary + Pharmacy/Clinical Model (Patient Services), with a secondary code of CRANAFAH, Cannabis Dispensary + Ancillary Retail (Accessories, CBD/Hemp, Merchandise). Its NAICS code is 325411 and its SIC code is 2834.